Fulvaa 250 mg Prefilled Syringe Injection 5 ml

Fulvaa 250 mg Prefilled Syringe Injection 5 ml belongs to the class of estrogen blockers used to treat breast cancer in postmenopausal women. Breast cancer is a type of cancer that develops when the breast cells begin to grow abnormally.

Fulvaa 250 mg Prefilled Syringe Injection 5 ml contains Fulvestrant, which works by inhibiting some of the actions of estrogen (female sex hormone which may help cancer cells grow in women with breast cancer) and reducing the amount that is in the body. Thus, it helps in reducing breast cancer tumour growth.

Fulvaa 250 mg Prefilled Syringe Injection 5 ml will be administered by a healthcare professional; do not self-administer. In some cases, Fulvaa 250 mg Prefilled Syringe Injection 5 ml may cause certain common side effects such as injection site reactions like pain and/or inflammation, weakness, nausea, tiredness, headache or joint and musculoskeletal pain. Most of these side effects of Fulvaa 250 mg Prefilled Syringe Injection 5 ml do not require medical attention and gradually resolve over time. However, if these side effects persist or worsen, please consult your doctor.

If you are allergic to Fulvestrant or any other medicines, please tell your doctor. Fulvaa 250 mg Prefilled Syringe Injection 5 ml is not recommended for pregnant women as it may harm an unborn baby. Fulvaa 250 mg Prefilled Syringe Injection 5 ml is contraindicated for use during lactation. Avoid alcohol consumption while receiving Fulvaa 250 mg Prefilled Syringe Injection 5 ml. Avoid driving or operating machinery if you feel tired or weak after receiving Fulvaa 250 mg Prefilled Syringe Injection 5 ml.

Fulvaa 250 mg Prefilled Syringe Injection 5 ml is used in the treatment of Breast cancer in postmenopausal women. The detailed uses of Fulvaa 250 mg Prefilled Syringe Injection 5 ml are as follows:

• Treatment of breast cancer: Fulvaa 250 mg Prefilled Syringe Injection 5 ml is used in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer in postmenopausal women.
• Treatment of progressed cancer: Fulvaa 250 mg Prefilled Syringe Injection 5 ml is prescribed when the cancer has progressed following prior endocrine therapy.

• Your doctor will decide the dosage and timing of Fulvaa 250 mg Prefilled Syringe Injection 5 ml based on the stage of cancer and your body’s response to the treatment. Usually, it is given every two weeks for the first three doses, then once monthly.
• Fulvaa 250 mg Prefilled Syringe Injection 5 ml will be administered by a doctor or nurse in a medical facility.
• Do not self-administer.

Fulvaa 250 mg Prefilled Syringe Injection 5 ml contains Fulvestrant, used to treat breast cancer in postmenopausal women. Additionally, Fulvaa 250 mg Prefilled Syringe Injection 5 ml may be used in combination with palbociclib to treat women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or has spread to other parts of the body (metastatic).

If you are allergic to Fulvestrant or any other medicines, please tell your doctor. Fulvaa 250 mg Prefilled Syringe Injection 5 ml is not recommended for pregnant women as it may harm an unborn baby. Using effective contraception while being treated with Fulvaa 250 mg Prefilled Syringe Injection 5 ml and for two years after the last dose is advised. Fulvaa 250 mg Prefilled Syringe Injection 5 ml is contraindicated for use during lactation. Avoid alcohol consumption while receiving Fulvaa 250 mg Prefilled Syringe Injection 5 ml. Avoid driving or operating machinery if you feel tired or weak after receiving Fulvaa 250 mg Prefilled Syringe Injection 5 ml.